



Leading Sponsor Enrolls 30,000+ Participants in Just Over 3 Months With WCG Study Acceleration


THE CHALLENGE

A Top 5 pharmaceutical company initiated a global vaccine study to test the safety, tolerability, immunogenicity, and efficacy of their new molecular entity (NME)—one that would become critical to the masses. Moreover, the client required an ethnically diverse population for their vaccine trial in support of FDA and SAHPRA approval. The urgency to deliver speed and true outcomes was set upon a backdrop of lost healthcare jobs and a global public health emergency due to the novel coronavirus (COVID-19).

THE RESULTS

At the core of the results, sites were optimized to meet their full potential, delivering comprehensive recruitment, enrollment, and retention—without sacrificing data integrity. Moreover, the Sponsor received an Emergency Use Authorization (EUA) in 10 months.





“WCG enabled critical efficiency that allowed us to effectively support our investigative sites and meet aggressive research timelines.”

—VP, TOP 5 PHARMA

OUR SOLUTION



We launched a multi-channel media campaign to spread awareness



Set up a secure and easy-to-use website to receive inbound participant inquiries



Deployed our PIC (Participant Interaction Center) to follow up with participants



Placed 225 CRCs* in the first 6 weeks to enroll and retain participants

**Clinical Research Coordinators*

REQUEST CONSULTATION

www.wcgclinical.com